Oragenics, Inc.
OGENHealthcare|Biotechnology|US
$0.35
+0.00 (+0.04%)
DCF Value
$1.56
Tangible Book / Share
$0.83
Cash / Share
$0.87
Financials
Financial Snapshot
Market Cap
$1.6M
Enterprise Value
-$2.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$10.1M
Cash & Investments
$3.9M
Net Cash
$3.9M
Free Cash Flow (TTM)
-$10.2M
Operating CF (TTM)
-$10.2M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$3.9M
Quarterly Burn
$2.6M
Monthly Burn
$850.6K
Est. Runway
~1.5 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.1M | $6.2M | $20.2M | $18.3M | $17.6M | $27.3M | $11.4M | $3.5M | $864.8K | $8.4M | $3.9M | |
| Operating Cash Flow | -$7.1M | -$6.4M | -$9.1M | -$13.0M | -$17.0M | -$13.5M | -$15.2M | -$7.3M | -$8.6M | -$9.25B | -$10.2M | |
| Free Cash Flow | -$7.1M | -$6.4M | -$9.2M | -$13.0M | -$17.0M | -$13.5M | -$15.4M | -$8.3M | -$8.6M | -$9.25B | -$10.2M | |
| Capital Expenditure | -$27.2K | $0.00 | -$124.7K | -$25.2K | $0.00 | -$43.9K | -$127.5K | -$1.0M | $0.00 | -$3.00 | $1.00 | |
| Financing Cash Flow | $4.5M | $8.4M | $23.2M | $11.1M | $16.3M | $23.1M | -$494.9K | $283.9K | $6.0M | $16.78B | $12.1M |
R&D Spending
R&D (TTM)
$3.4M
R&D Intensity
—
R&D Growth vs Prior
-99.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $4.8M | $3.5M | $6.0M | $12.1M | $22.1M | $10.6M | $10.1M | $15.5M | $4.1M | $2.39B | $3.4M | |
| SG&A | $3.8M | $3.2M | $4.0M | $3.8M | $4.5M | $5.3M | $4.5M | $5.5M | $6.4M | $6.97B | $7.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $75.0K | $65.8K | $30.1K | $62.6K | $22.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$75.0K | -$65.8K | -$30.1K | -$62.6K | -$22.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $4.8M | $3.5M | $6.0M | $12.1M | $22.1M | $10.6M | $10.1M | $15.5M | $4.1M | $2.39B | $3.4M | |
| SG&A | $3.8M | $3.2M | $4.0M | $3.8M | $4.5M | $5.3M | $4.5M | $5.5M | $6.4M | $6.97B | $7.0M | |
| Operating Income | -$8.5M | -$6.7M | -$10.0M | -$15.9M | -$26.6M | -$15.8M | -$14.4M | -$20.9M | -$10.6M | -$9.4M | -$10.5M | |
| Interest Expense | $4.1K | $216.3K | $5.8K | $7.3K | $10.7K | $15.8K | $15.1K | $30.6K | $29.8K | $785.9K | $18.6K | |
| Pretax Income | -$8.5M | -$6.7M | -$9.9M | -$15.6M | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$10.0M | -$10.3M | |
| Net Income | -$7.0M | -$6.7M | -$9.9M | -$15.6M | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$9.8M | -$10.1M | |
| EPS (Diluted) | -94.33 | -81.99 | -45.62 | -22.10 | -28.05 | -8.09 | -7.11 | -9.18 | -1.60 | -4.56 | -3.58 | |
| EBITDA | -$8.4M | -$6.4M | -$9.9M | -$15.5M | -$26.6M | -$15.7M | -$14.2M | -$20.6M | -$10.5M | $762.2M | -$7.2M | |
| Shares Out. (M) | 0.07 | 0.08 | 0.22 | 0.70 | 0.94 | 1.88 | 2.01 | 2.25 | 6.62 | 2.16 | 4.43 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.1M | $6.2M | $20.2M | $18.3M | $17.6M | $27.3M | $11.4M | $3.5M | $864.8K | $4.4M | $3.9M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.0M | $0.00 | |
| Total Current Assets | $4.2M | $7.2M | $21.9M | $18.8M | $18.0M | $27.7M | $14.3M | $3.9M | $1.5M | $10.1M | $5.5M | |
| Total Assets | $4.3M | $7.2M | $22.0M | $19.8M | $18.7M | $28.2M | $14.8M | $5.0M | $1.5M | $10.1M | $5.5M | |
| Total Current Liabilities | $1.3M | $898.5K | $1.2M | $1.9M | $1.3M | $1.4M | $1.6M | $1.8M | $1.7M | $1.8M | $1.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.3M | $898.5K | $1.2M | $2.5M | $1.8M | $1.7M | $1.7M | $1.8M | $1.7M | $1.8M | $1.8M | |
| Stockholders' Equity | $3.0M | $6.3M | $20.9M | $17.2M | $16.8M | $26.5M | $13.0M | $3.2M | -$211.9K | $8.3M | $3.7M | |
| Retained Earnings | -$94.7M | -$101.4M | -$111.4M | -$127.4M | -$154.4M | -$171.3M | -$185.6M | -$206.2M | -$216.8M | -$226.6M | -$231.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.1M | -$6.4M | -$9.1M | -$13.0M | -$17.0M | -$13.5M | -$15.2M | -$7.3M | -$8.6M | -$9.25B | -$10.2M | |
| Capital Expenditure | -$27.2K | $0.00 | -$124.7K | -$25.2K | $0.00 | -$43.9K | -$127.5K | -$1.0M | $0.00 | -$3.00 | $1.00 | |
| Free Cash Flow | -$7.1M | -$6.4M | -$9.2M | -$13.0M | -$17.0M | -$13.5M | -$15.4M | -$8.3M | -$8.6M | -$9.25B | -$10.2M | |
| Investing Cash Flow | $1.7M | $0.00 | -$124.7K | -$25.2K | $0.00 | -$43.9K | -$115.5K | -$936.3K | $0.00 | $0.00 | $4.0M | |
| Financing Cash Flow | $4.5M | $8.4M | $23.2M | $11.1M | $16.3M | $23.1M | -$494.9K | $283.9K | $6.0M | $16.78B | $12.1M | |
| Issuance of Stock | $2.6M | $6.2M | $13.9M | $0.00 | $11.3M | $29.3M | $69.3K | $849.9K | $6.7M | $17.7M | $15.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$5.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$158.1K | $2.2M | $0.00 | -$252.9K | -$197.3K | -$525.0K | -$564.2K | -$566.0K | -$693.1K | -$872.6K | -$3.0M | |
| Stock Based Comp. | $638.4K | $560.5K | $1.0M | $553.0K | $1.5M | $1.7M | $742.2K | $1.0M | $516.0K | $642.4M | $110.1K | |
| Net Change in Cash | -$1.0M | $2.1M | $14.0M | -$1.9M | -$628.4K | $9.6M | -$15.8M | -$7.9M | -$2.6M | $7.53B | $1.9M |
Dilution Tracker
Shares outstanding grew 128.9% over 5 years — significant dilution
Shares Outstanding
5M
5-Year Share Growth
+128.9%
Stock Issuance (TTM)
$15.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.07 | 0.08 | 0.22 | 0.70 | 0.94 | 1.88 | 2.01 | 2.25 | 6.62 | 2.16 | 4.43 | |
| Change vs Prior % | — | 10.4% | 164.7% | 224.3% | 33.7% | 99.7% | 6.7% | 12.0% | 194.3% | -67.4% | 105.3% | |
| Stock Issuance | $2.6M | $6.2M | $13.9M | $0.00 | $11.3M | $29.3M | $69.3K | $849.9K | $6.7M | $17.7M | $15.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$5.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $638.4K | $560.5K | $1.0M | $553.0K | $1.5M | $1.7M | $742.2K | $1.0M | $516.0K | $642.4M | $110.1K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -236.5% | -106.6% | -47.5% | -90.4% | -156.9% | -59.3% | -109.8% | -652.0% | 4987.6% | -118.9% | -144.2% | |
| ROA % | -162.8% | -93.3% | -45.0% | -78.8% | -141.5% | -55.7% | -96.8% | -415.9% | -717.7% | -97.8% | -183.6% | |
| ROIC % | -281.7% | -105.0% | -47.2% | -87.2% | -150.1% | -57.8% | -105.8% | -598.9% | -9052.2% | -108.5% | -279.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -110.8% | 12.3% | 54.2% | -108.0% | -35203.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 26.7% | 21.4% | -48.8% | -58.9% | -67.8% | 40.8% | 8.6% | -45.0% | 49.5% | 11.3% | |
| Net Income | 40.1% | 4.0% | -47.3% | -57.1% | -69.7% | 40.6% | 9.1% | -44.6% | 48.8% | 6.9% | |
| EPS (Diluted) | 50.9% | 13.1% | 44.4% | 51.6% | -26.9% | 71.2% | 12.1% | -29.1% | 82.6% | -185.0% | |
| Operating Cash Flow | -38.6% | 10.1% | -42.7% | -43.3% | -30.3% | 20.5% | -13.1% | 52.1% | -17.9% | -107448.9% | |
| Free Cash Flow | -36.4% | 10.4% | -44.6% | -41.6% | -30.0% | 20.3% | -13.6% | 46.0% | -3.7% | -107448.9% | |
| R&D Expense | -46.0% | -25.6% | 68.7% | 102.9% | 82.4% | -52.1% | -4.9% | 53.8% | -73.4% | 58052.8% | |
| SG&A Expense | 6.9% | -16.1% | 26.5% | -6.6% | 20.7% | 16.3% | -15.0% | 21.7% | 18.2% | 108053.8% | |
| Total Assets | -25.4% | 67.4% | 205.6% | -10.4% | -5.4% | 51.1% | -47.7% | -66.3% | -70.4% | 583.7% | |
| Book Value / Share | -48.5% | 92.8% | 24.9% | -74.6% | -26.9% | -21.3% | -54.0% | -78.3% | -102.3% | 12098.5% | |
| Debt | 4.8% | 21.2% | 54.3% | 688.7% | -8.2% | -11.3% | -21.7% | -48.4% | 1.9% | -30.8% | |
| Diluted Shares | 21.7% | 10.4% | 164.7% | 224.3% | 33.7% | 99.7% | 6.7% | 12.0% | 194.3% | -67.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.42
10Y Low / Med / High0.20 / 45.21 / 243.62
EV/EBITDA0.32
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.56
Tangible Book / Share
$0.83
Net Current Assets / Share
$0.81
Graham Net-Net
$0.46
Cash / Share
$0.87
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -103.02 | -51.57 | -33.89 | -42.60 | -28.81 | -99.23 | -26.61 | -18.40 | -6.92 | -0.17 | -0.10 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 243.62 | 54.96 | 16.09 | 38.50 | 45.21 | 57.04 | 29.21 | 119.95 | -346.28 | 0.20 | 0.42 | |
| EV/EBITDA | -85.35 | -52.88 | -31.98 | -41.70 | -28.01 | -94.82 | -25.95 | -18.30 | -6.91 | -0.00 | 0.32 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-63.83
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $2.3M |
| Net Income | -$1.5M | -$906.0K | -$841.3K |
| EPS | $-0.69 | $-0.42 | $-0.39 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Product
| Segment | 2022 | 2023 |
|---|---|---|
| Grant | $250.0K | $250.0K |